| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
| Targets |
BRL-52537 HCl targets the kappa-opioid receptor (KOR), a G protein-coupled receptor that is activated by endogenous opioid peptides like dynorphin. It exhibits exceptional selectivity for KOR over the mu-opioid receptor (MOR), with Ki values of 0.24 nM for KOR and 1560 nM for MOR. This high selectivity makes it a valuable tool for studying KOR-specific functions.
|
|---|---|
| ln Vitro |
In vitro, BRL-52537 HCl is a potent and selective KOR agonist. It binds to the KOR with a Ki of 0.24 nM. This high affinity translates to potent activation of KOR-mediated signaling pathways. Its selectivity is demonstrated by its much lower affinity for the mu-opioid receptor (Ki = 1560 nM).
|
| ln Vivo |
In vivo, BRL-52537 HCl has demonstrated neuroprotective effects. It attenuates early stroke damage in animal models. It also reduces toluene-induced nitric oxide (NO) production, which is a potential neuroprotective mechanism. These findings suggest that KOR agonists may have therapeutic potential in treating ischemic brain injury.
|
| Enzyme Assay |
The binding affinity and selectivity of BRL-52537 HCl are assessed using radioligand binding assays. Membranes from cells expressing the KOR or MOR are incubated with a radiolabeled ligand and varying concentrations of BRL-52537 HCl. The Ki values are calculated from competition curves. Functional activity can be assessed using assays that measure KOR-mediated signaling, such as GTPγS binding.
|
| Cell Assay |
The cellular activity of BRL-52537 HCl is evaluated in cell lines expressing the KOR. Cells are treated with the compound, and its effect on receptor activation and downstream signaling is measured. This can include measuring the inhibition of adenylyl cyclase activity or the activation of MAPK pathways. The compound's potency (EC50) for inducing these effects is determined.
|
| Animal Protocol |
In animal studies, BRL-52537 HCl is typically administered via intraperitoneal (i.p.) or intravenous (i.v.) injection. In models of stroke, it is given to assess its neuroprotective effects, with endpoints such as infarct volume and neurological deficit scores. In models of pain, its analgesic effects can be evaluated. Dosing regimens are determined based on the compound's pharmacokinetics.
|
| ADME/Pharmacokinetics |
BRL-52537 HCl is a small molecule with a molecular weight of 391.76 and a formula of C18H25Cl3N2O. It is typically stored as a powder at -20°C. It is soluble in DMSO. The compound's hydrochloride salt form enhances its aqueous solubility. Detailed pharmacokinetic parameters, such as half-life and bioavailability, are available in the primary literature.
|
| Toxicity/Toxicokinetics |
Toxicology data for BRL-52537 HCl is limited, as it is a research compound. However, as a KOR agonist, its pharmacological effects are well-characterized. Potential side effects are related to KOR activation and can include dysphoria, sedation, and diuresis. Its use is limited to research applications and it is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
BRL-52537 HCl (CAS: 112282-24-3) is a widely used and highly selective pharmacological tool for studying the kappa-opioid receptor. Its exceptional potency (Ki = 0.24 nM) and selectivity over the mu-opioid receptor make it a key compound for investigating KOR biology. It is a standard reference agonist in opioid research and has been instrumental in elucidating the role of KOR in pain, neuroprotection, and addiction.
|
| Molecular Formula |
C18H25CL3N2O
|
|---|---|
| Molecular Weight |
391.76
|
| Exact Mass |
390.103
|
| CAS # |
112282-24-3
|
| PubChem CID |
11315337
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.69
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
401
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCN(C(C1)CN2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl.Cl
|
| InChi Key |
NGVLSOWJSUUYDE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H24Cl2N2O.ClH/c19-16-7-6-14(11-17(16)20)12-18(23)22-10-2-1-5-15(22)13-21-8-3-4-9-21;/h6-7,11,15H,1-5,8-10,12-13H2;1H
|
| Chemical Name |
2-(3,4-dichlorophenyl)-1-[2-(pyrrolidin-1-ylmethyl)piperidin-1-yl]ethanone;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5526 mL | 12.7629 mL | 25.5258 mL | |
| 5 mM | 0.5105 mL | 2.5526 mL | 5.1052 mL | |
| 10 mM | 0.2553 mL | 1.2763 mL | 2.5526 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
